Management of Adverse Events From the Combination of Rituximab and Lenalidomide (R2) in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphomas

Frontline treatment for patients with indolent non-Hodgkin lymphoma (iNHL) often includes immunochemotherapy. Although most patients respond to initial treatment, relapse is common. Recent results from the phase III AUGMENT trial showed that combining rituximab with the immunomodulatory drug lenalidomide (R2) significantly improved efficacy over rituximab monotherapy in patients with recurrent iNHL. As a result of these data, R2 was approved in the US (FDA) and Japan (PMDA) for previously treated adult patients with follicular and marginal zone lymphoma; and by the European Medicine Agency and Swissmedic for previously treated adult patients with follicular lymphoma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research